2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Antitrust enforcement is likely to return to its established norms, Jay Ezrielev writes in a guest commentary.

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Over the last 10 months, the Congress government secured agreements for 140 Life Sciences or pharmaceutical projects ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

As of 10:59 am Eastern time, the S&P 500 was virtually flat, the Dow Jones Industrial Average was up 0.3 per cent, and the ...

Wall Street stocks were flat on Wednesday after data showed consumer price inflation rose last month. At the opening bell, ...